{"id":58717,"date":"2026-03-04T12:55:25","date_gmt":"2026-03-04T04:55:25","guid":{"rendered":"https:\/\/flcube.com\/?p=58717"},"modified":"2026-03-04T12:55:25","modified_gmt":"2026-03-04T04:55:25","slug":"antengene-licenses-atg-201-to-ucb-in-1-1b-deal-cd19-cd3-t-cell-engager-targets-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58717","title":{"rendered":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Antengene Corp., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/6996:HKG\">HKG:\u202f6996<\/a>)<\/strong> announced a <strong>licensing agreement<\/strong> with <strong>UCB (<a href=\"https:\/\/www.google.com\/finance\/quote\/UCB:EBR\">EBR:\u202fUCB<\/a>)<\/strong>, granting the <strong>Belgium\u2011based biopharma exclusive global rights<\/strong> to <strong>ATG-201<\/strong>, a <strong>CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody<\/strong>. The deal includes <strong>USD\u202f80\u202fmillion upfront and near\u2011term milestones<\/strong> and <strong>potential payments exceeding USD\u202f1.1\u202fbillion<\/strong>, positioning ATG-201 as a <strong>next\u2011generation autoimmune therapy<\/strong> leveraging <strong>spatial steric hindrance masking technology<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Antengene Corp., Ltd (HKG:\u202f6996)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>UCB (EBR:\u202fUCB)<\/td><\/tr><tr><td><strong>Licensed Asset<\/strong><\/td><td>ATG-201<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>CD19\/CD3 bispecific T\u2011cell engager (TCE)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Spatial steric hindrance masking (AnTenGager platform)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global exclusive rights<\/td><\/tr><tr><td><strong>Upfront + Near\u2011Term<\/strong><\/td><td><strong>USD\u202f80\u202fmillion<\/strong> (USD\u202f60\u202fM upfront + USD\u202f20\u202fM milestone)<\/td><\/tr><tr><td><strong>Future Milestones<\/strong><\/td><td>Potentially <strong>&gt;\u202fUSD\u202f1.1\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered based on future net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Responsibility<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>IND Filing<\/strong><\/td><td>Antengene<\/td><td>Q1\u202f2026 (China + Australia)<\/td><\/tr><tr><td><strong>Phase I (First\u2011in\u2011Human)<\/strong><\/td><td>Antengene<\/td><td>China + Australia<\/td><\/tr><tr><td><strong>Post\u2011Phase I Development<\/strong><\/td><td>UCB<\/td><td>Global transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-atg-201\">Drug Profile \u2013 ATG-201<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>CD19<\/strong> (B\u2011cell marker) + <strong>CD3<\/strong> (T\u2011cell activation)<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Bispecific T\u2011cell engager (TCE)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td><strong>Spatial steric hindrance masking<\/strong> \u2013 Antengene&#8217;s AnTenGager platform<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Redirects T\u2011cells to deplete CD19\u2011expressing B cells<\/td><\/tr><tr><td><strong>Indication Focus<\/strong><\/td><td><strong>B\u2011cell related autoimmune diseases<\/strong> (vs. oncology TCEs targeting B\u2011cell malignancies)<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Masking technology potentially reduces off\u2011tumor toxicity; enables safer chronic autoimmune dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune TCE Innovation:<\/strong> ATG-201 represents a <strong>paradigm shift<\/strong>\u2014applying <strong>T\u2011cell engager technology<\/strong> (proven in oncology: Blincyto) to <strong>autoimmune diseases<\/strong>, where <strong>B\u2011cell depletion<\/strong> is established (rituximab) but <strong>TCEs may offer superior depth and durability<\/strong>.<\/li>\n\n\n\n<li><strong>Spatial Masking Advantage:<\/strong> The <strong>steric hindrance masking technology<\/strong> may <strong>limit systemic cytokine release<\/strong> and <strong>reduce infusion reactions<\/strong>, enabling <strong>outpatient administration<\/strong> and <strong>chronic autoimmune management<\/strong>\u2014critical differentiators vs. unmasked TCEs.<\/li>\n\n\n\n<li><strong>UCB Autoimmune Strategy:<\/strong> UCB gains a <strong>novel B\u2011cell depletion mechanism<\/strong> complementing its <strong>established immunology franchise<\/strong> (Cimzia, Bimzelx); ATG-201 addresses <strong>rituximab\u2011resistant or \u2011relapsing autoimmune populations<\/strong>.<\/li>\n\n\n\n<li><strong>Antengene Platform Validation:<\/strong> The <strong>AnTenGager platform<\/strong>\u2014previously generating <strong>ATG-037 (CD73 inhibitor)<\/strong>\u2014now yields a <strong>second partnered asset<\/strong>, validating <strong>bispecific discovery capabilities<\/strong> and <strong>attracting further global licensing interest<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Autoimmune B\u2011Cell Depletion Market<\/strong><\/td><td>~\u202f$15\u202fbillion (rituximab, ocrelizumab); significant unmet need in SLE, MS, myasthenia gravis with incomplete responses<\/td><\/tr><tr><td><strong>TCE Autoimmune Trend<\/strong><\/td><td>Teclistamab (BCMA\u00d7CD3) approved for myeloma; CD19\u00d7CD3 TCEs for autoimmunity represent next wave; Epcoritamab (Genmab\/AbbVie) in SLE trials<\/td><\/tr><tr><td><strong>UCB Competitive Position<\/strong><\/td><td>ATG-201 adds novel mechanism to Cimzia (TNF) + Bimzelx (IL\u201117A\/F) portfolio; creates B\u2011cell\u2011targeted option<\/td><\/tr><tr><td><strong>Antengene Global Reach<\/strong><\/td><td>Second major partnership (following Astellas collaboration) establishes Antengene as <strong>preferred China biotech partner<\/strong> for autoimmune innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IND filing timelines, first\u2011in\u2011human safety outcomes, and autoimmune efficacy signals for ATG-201. Actual results may differ due to risks including TCE\u2011mediated cytokine release, competitive CD19\u2011targeting programs, and UCB integration execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[136,2015,926,28,131],"class_list":["post-58717","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-antengene","tag-ebr-ucb","tag-hkg-6996","tag-multi-specific-antibodies","tag-ucb"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58717\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58717\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T04:55:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\\\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases\",\"datePublished\":\"2026-03-04T04:55:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717\"},\"wordCount\":481,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"EBR: UCB\",\"HKG: 6996\",\"Multi-specific antibodies\",\"UCB\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58717#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58717\",\"name\":\"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\\\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-04T04:55:25+00:00\",\"description\":\"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\\\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58717\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58717#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\\\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58717","og_locale":"en_US","og_type":"article","og_title":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases","og_description":"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.","og_url":"https:\/\/flcube.com\/?p=58717","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T04:55:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58717#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58717"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases","datePublished":"2026-03-04T04:55:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58717"},"wordCount":481,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","EBR: UCB","HKG: 6996","Multi-specific antibodies","UCB"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58717#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58717","url":"https:\/\/flcube.com\/?p=58717","name":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-04T04:55:25+00:00","description":"Antengene Corp., Ltd (HKG:\u202f6996) announced a licensing agreement with UCB (EBR:\u202fUCB), granting the Belgium\u2011based biopharma exclusive global rights to ATG-201, a CD19\/CD3 bispecific T\u2011cell engager (TCE) antibody. The deal includes USD\u202f80\u202fmillion upfront and near\u2011term milestones and potential payments exceeding USD\u202f1.1\u202fbillion, positioning ATG-201 as a next\u2011generation autoimmune therapy leveraging spatial steric hindrance masking technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58717#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58717"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58717#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene Licenses ATG-201 to UCB in $1.1B+ Deal \u2013 CD19\/CD3 T\u2011Cell Engager Targets Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58717"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58717\/revisions"}],"predecessor-version":[{"id":58718,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58717\/revisions\/58718"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}